Program
clemizole hydrochloride
Also written as “Clemizole HCl”, “EPX-100” and “EPX-100 (Clemizole Hydrochloride)”.
Its studies are mostly in Epilepsies, Myoclonic · Lennox Gastaut Syndrome · Hepatitis C · Carcinoma, Hepatocellular, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Epygenix | 53 open or running | phase 3since Jul 6, 2020 | Aug 22, 2019 | Dec 30, 2026phase 1 · NCT07879170 |
| Eiger BioPharmaceuticals | 10 open or running | phase 1since Jul 23, 2009 | Jul 23, 2009 | none ahead |
| Eiger Group International | 10 open or running | phase 2since Feb 14, 2017 | Feb 14, 2017 | none ahead |
Also a collaborator on its studies: Harmony Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 23, 2009First study: phase 1 study in Hepatitis CNew to Eiger BioPharmaceuticalsEiger BioPharmaceuticals · NCT00945880 · 12 enrolled
- Feb 14, 2017Eiger Group International’s first study: phase 2 study in Carcinoma, HepatocellularNew to Eiger Group InternationalEiger Group International · NCT03069508 · 12 enrolled · Turkey
- Aug 22, 2019Epygenix’s first study: phase 1 study in Epilepsies, MyoclonicNew to EpygenixEpygenix · NCT04069689 · 24 enrolled · United States
- Jul 6, 2020Phase 3 study in Epilepsies, MyoclonicEpygenix · NCT04462770 · 150 planned · United States, Argentina, Brazil and more
- Sep 23, 2021Phase 3 study in Lennox Gastaut SyndromeEpygenix · NCT05066217 · 260 planned · United States, China, Hungary and more
- Sep 11, 20262 phase 1 studiesEpygenix · NCT07824193, NCT07879170
Ahead
- Nov 1, 2026Primary completion: phase 3 study in Lennox Gastaut SyndromeEpygenix · NCT05066217
- Dec 30, 2026Primary completion: phase 1 study in Healthy ParticipantsEpygenix · NCT07879170
- Apr 2027Primary completion: phase 3 study in Epilepsies, MyoclonicEpygenix · NCT04462770
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07879170Healthy Participants · United States | 1 | Recruiting | Epygenix | Dec 30, 2026 | 88 |
| NCT07824193Drug Drug Interaction · United States | 1 | Completed | Epygenix | Apr 3, 2025 | 54 |
| NCT05066217Lennox Gastaut Syndrome · United States, China, Hungary and more | 3 | Recruiting | Epygenix | Nov 1, 2026 | 260 |
| NCT04462770Epilepsies, Myoclonic · United States, Argentina, Brazil and more | 3 | Recruiting | Epygenix | Apr 2027 | 150 |
| NCT04069689Epilepsies, Myoclonic · United States | 1 | Completed | Epygenix | Nov 27, 2019 | 24 |
| NCT03069508Carcinoma, Hepatocellular · Turkey | 2 | UNKNOWN | Eiger Group International | Dec 31, 2017 | 12 |
| NCT00945880Hepatitis C | 1 | Completed | Eiger BioPharmaceuticals | Aug 2010 | 12 |
How it is read
Names in the registry
- “Clemizole HCl”, 2 entries
- “EPX-100”, 2 entries
- “EPX-100 (Clemizole Hydrochloride)”, 1 entry
- “clemizole hydrochloride”, 1 entry
- “Clemizole Hydrochloride”, 1 entry
Conditions, from the studies’ own filings
- Epilepsies, Myoclonic, 2 studies
- Lennox Gastaut Syndrome, 1 study
- Hepatitis C, 1 study
- Carcinoma, Hepatocellular, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.